CA-CAS-01-A : A Permissive Cell Line for Isolation and Live Attenuated Vaccine Development Against African Swine Fever Virus
© 2024. The Author(s)..
African swine fever virus (ASFV) is the causative agent of the highly lethal African swine fever disease that affects domestic pigs and wild boars. In spite of the rapid spread of the virus worldwide, there is no licensed vaccine available. The lack of a suitable cell line for ASFV propagation hinders the development of a safe and effective vaccine. For ASFV propagation, primary swine macrophages and monocytes have been widely studied. However, obtaining these cells can be time-consuming and expensive, making them unsuitable for mass vaccine production. The goal of this study was to validate the suitability of novel CA-CAS-01-A (CAS-01) cells, which was identified as a highly permissive cell clone for ASFV replication in the MA-104 parental cell line for live attenuated vaccine development. Through a screening experiment, maximum ASFV replication was observed in the CAS-01 cell compared to other sub-clones of MA-104 with 14.89 and log10 7.5 ± 0.15 Ct value and TCID50/ml value respectively. When CAS-01 cells are inoculated with ASFV, replication of ASFV was confirmed by Ct value for ASFV DNA, HAD50/ml assay, TCID50/ml assay, and cytopathic effects and hemadsoption were observed similar to those in primary porcine alveolar macrophages after 5th passage. Additionally, we demonstrated stable replication and adaptation of ASFV over the serial passage. These results suggest that CAS-01 cells will be a valuable and promising cell line for ASFV isolation, replication, and development of live attenuated vaccines.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:62 |
|---|---|
| Enthalten in: |
Journal of microbiology (Seoul, Korea) - 62(2024), 2 vom: 25. Feb., Seite 125-134 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lee, Seung-Chul [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
African swine fever virus (ASFV) |
|---|
| Anmerkungen: |
Date Completed 17.04.2024 Date Revised 25.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s12275-024-00116-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369703162 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369703162 | ||
| 003 | DE-627 | ||
| 005 | 20240425233139.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240315s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12275-024-00116-1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1386.xml |
| 035 | |a (DE-627)NLM369703162 | ||
| 035 | |a (NLM)38480615 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lee, Seung-Chul |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a CA-CAS-01-A |b A Permissive Cell Line for Isolation and Live Attenuated Vaccine Development Against African Swine Fever Virus |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.04.2024 | ||
| 500 | |a Date Revised 25.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a African swine fever virus (ASFV) is the causative agent of the highly lethal African swine fever disease that affects domestic pigs and wild boars. In spite of the rapid spread of the virus worldwide, there is no licensed vaccine available. The lack of a suitable cell line for ASFV propagation hinders the development of a safe and effective vaccine. For ASFV propagation, primary swine macrophages and monocytes have been widely studied. However, obtaining these cells can be time-consuming and expensive, making them unsuitable for mass vaccine production. The goal of this study was to validate the suitability of novel CA-CAS-01-A (CAS-01) cells, which was identified as a highly permissive cell clone for ASFV replication in the MA-104 parental cell line for live attenuated vaccine development. Through a screening experiment, maximum ASFV replication was observed in the CAS-01 cell compared to other sub-clones of MA-104 with 14.89 and log10 7.5 ± 0.15 Ct value and TCID50/ml value respectively. When CAS-01 cells are inoculated with ASFV, replication of ASFV was confirmed by Ct value for ASFV DNA, HAD50/ml assay, TCID50/ml assay, and cytopathic effects and hemadsoption were observed similar to those in primary porcine alveolar macrophages after 5th passage. Additionally, we demonstrated stable replication and adaptation of ASFV over the serial passage. These results suggest that CAS-01 cells will be a valuable and promising cell line for ASFV isolation, replication, and development of live attenuated vaccines | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a African swine fever virus (ASFV) | |
| 650 | 4 | |a CA-CAS-01-A (CAS-01) | |
| 650 | 4 | |a Virus adaptation | |
| 650 | 7 | |a Vaccines, Attenuated |2 NLM | |
| 650 | 7 | |a Viral Proteins |2 NLM | |
| 700 | 1 | |a Kim, Yongkwan |e verfasserin |4 aut | |
| 700 | 1 | |a Cha, Ji-Won |e verfasserin |4 aut | |
| 700 | 1 | |a Chathuranga, Kiramage |e verfasserin |4 aut | |
| 700 | 1 | |a Dodantenna, Niranjan |e verfasserin |4 aut | |
| 700 | 1 | |a Kwon, Hyeok-Il |e verfasserin |4 aut | |
| 700 | 1 | |a Kim, Min Ho |e verfasserin |4 aut | |
| 700 | 1 | |a Jheong, Weonhwa |e verfasserin |4 aut | |
| 700 | 1 | |a Yoon, In-Joong |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Joo Young |e verfasserin |4 aut | |
| 700 | 1 | |a Yoo, Sung-Sik |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Jong-Soo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of microbiology (Seoul, Korea) |d 1998 |g 62(2024), 2 vom: 25. Feb., Seite 125-134 |w (DE-627)NLM096425555 |x 1976-3794 |7 nnns |
| 773 | 1 | 8 | |g volume:62 |g year:2024 |g number:2 |g day:25 |g month:02 |g pages:125-134 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s12275-024-00116-1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 62 |j 2024 |e 2 |b 25 |c 02 |h 125-134 | ||